Spark Therapeutics, Inc. (NASDAQ:ONCE) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07.
Submission of Matters to a Vote of Security Holders
On May 30, 2018, Spark Therapeutics, Inc. (the “Company”) held its previously announced Annual Meeting of Stockholders (the “Meeting”), at which a quorum was present. At the Meeting, the stockholders of the Company voted on the following three proposals:
1. The following nominees were elected to the Company’s Board of Directors (the “Board”) as Class III directors for terms expiring at the 2021 annual meeting of stockholders. The votes cast at the Meeting were as follows:
|
On the election of Jeffrey D. Marrazzo as a Class III director – 23,866,594 shares voted for and 7,106,441 shares withheld. |
|
On the election of Vincent J. Milano as a Class III director – 22,599,997 shares voted for and 8,373,038 shares withheld. |
|
On the election of Elliott Sigal, M.D., Ph.D. as a Class III director – 23,792,236 shares voted for and 7,180,799 shares withheld. |
There were 2,656,800 broker non-votes for this proposal.
2. A non-binding, advisory proposal on the compensation of the Company’s named executive officers was approved. The votes cast at the Meeting were as follows: 30,411,199 shares voted for, 553,339 shares voted against and 8,497 shares abstained. There were 2,656,800 broker non-votes for this proposal.
3. The appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2018 was ratified. The votes cast at the Meeting were as follows: 33,574,992 shares voted for, 44,330 shares voted against and 10,513 shares abstained. There were zero broker non-votes for this proposal.
About Spark Therapeutics, Inc. (NASDAQ:ONCE)
Spark Therapeutics, Inc. (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs). Its product candidates include SPK-CHM and SPK-FIX. Its product development portfolio includes product candidates targeting expression of genes in the liver, with an initial focus on hematologic disorders. It is engaged in the development and commercialization of SPK-FIX product candidates for the treatment of hemophilia B. The Company is developing a lead product candidate for the treatment of a form of Batten disease in SPK-TPP1 program. The Company is also conducting preclinical studies on a product candidate for the treatment of Huntington’s disease, a hereditary genetic disorder.
